Drugs / TAP311
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01632358 | Jun → Dec 2012 | hyperlipidemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01487460 | Nov 2011 → Jun 2012 | hyperlipidemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAP311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01632358 ↗ |
| Route | Oral | “Patients will receive TAP311 capsule orally once daily for 14 days.” NCT01632358 ↗ |